Vogenx, Inc. (VOGX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Vogenx (NASDAQ:VOGX) began a Phase 2b trial for mizagliflozin to treat post-bariatric hypoglycemia. The EMERGE trial will enroll 36 adults with recurrent hypoglycemia post-surgery, testing 5 mg and 10 mg doses against placebo. Mizagliflozin is an investigational SGLT1 inhibitor, with no FDA-approved treatments currently available for this condition.

Vogenx, Inc. (VOGX) began a Phase 2b trial for mizagliflozin in post-bariatric hypoglycemia, enrolling 36 U.S. patients. The 28-day study tests 5 mg and 10 mg doses, with hypoglycemic events as the primary endpoint.

Vogenx (NASDAQ:VOGX) initiated a Phase 2b trial for mizagliflozin, a treatment for post-bariatric hypoglycemia (PBH), a condition with no FDA-approved therapies. The EMERGE trial will enroll 36 adults, testing 5 mg and 10 mg doses against placebo. Mizagliflozin aims to reduce hypoglycemic events by delaying glucose absorption in the small intestine. Vogenx's CEO and CSO highlighted the trial's significance and the drug's potential.

Several biotech stocks reached 52-week highs on September 18, 2026. Vogenx (VOGX) shares surged to $38.41, driven by positive clinical trial results. HeartSciences (HSCS) rose 7% to $5.21, while HeartFlow (HTFL) increased 2% to $52.22. Freenome (FRNM) gained 5% to $17.25, and Halozyme (HALO) hit $112.66 after announcing a $1.3B offering.

William Wilkison reportedly owns 1.8 million shares of Vanguard Extended Duration Treasury ETF (VOGX), valued at $56.6 million. No insider trades have been filed by Wilkison in VOGX since 2021, according to SEC filings.

Vogenx, Inc. (VOGX) closed its initial public offering of 6.25 million shares at $13.00 per share, raising approximately $81.3 million before expenses. The biopharmaceutical company focuses on treatments for metabolic dysfunctions, including post-bariatric hypoglycemia and gastroparesis.